Indaptus Therapeutics has filed a notice of an exempt offering of securities to raise $2,246,500.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Indaptus Therapeutics is raising up to $2,246,500.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Indaptus Therapeutics
With the ability to harness both the bodys innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacterias natural ability to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.
To learn more about Indaptus Therapeutics, visit http://indaptusrx.com/
Indaptus Therapeutics Linkedin Page: https://www.linkedin.com/company/indaptus-therapeutics-inc/
Contact:
Nir Sassi, Chief Financial Officer
646-427-2727
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.